STRO Sutro Biopharma, Inc.

$20.52 +0.05%

Updated 17 d ago

Healthcare · Biological Products, (No Diagnostic Substances)

Sutro Biopharma, Inc. (STRO) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $340 million. Shares last traded at $20.52, 51.6% below their 52-week high. Over the past year the stock is up 106.2%. Net profit margin is -176.3%, below the peer median of 5.3%. Revenue grew 65.2% year over year.

Market Cap

$340M

Shares Out

16.6M

EPS (TTM)

$-20.15

P/E Ratio

—

P/S Ratio

3.32

P/B Ratio

—

Dividend / Share

—

Dividend Yield

—

52-Week High

$42.38

52-Week Low

$7.21

Volume

4,533

Avg Vol (3m)

16,377.365

Performance

-3.80%

-18.25%

-28.53%

-8.94%

YTD

+86.72%

+106.23%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. STRO split history →

Technicals

RSI (14)

38.90

SMA (50)

$24.77

SMA (200)

$22.18

Price vs SMA50

-17.16%

Price vs SMA200

-7.50%

ATR (14)

$1.64

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$102M

Net Income

$-181M

Gross Margin

—

Operating Margin

-142.5%

Net Margin

-176.3%

Return on Equity

174.8%

Return on Assets

-92.9%

Current Ratio

3.32

Debt / Equity

-0.04

Revenue Growth (YoY)

+65.2%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q2 2026	$-5.19	2026-08-12
Q1 2026	$-2.94	2026-05-14
FY 2025	$-22.49	2026-03-23
Q3 2025	$-1.71	2025-11-06
Q2 2026	$-10.31	2026-08-12
Q1 2026	$-9.08	2026-05-14

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

STRO vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated 17 d ago

P/S vs peers

3.32 / 19.49 med

-83% discount

Net margin vs peers

-176.3% / 5.3% med

below median

1–14 of 14


AMGN	Amgen	$240.1B	27.47	6.30	23.0%	+0.31%
GILD	Gilead Sciences	$187.5B	-57.87	6.16	-10.6%	+1.09%
MRNA	Moderna	$58.8B	-18.68	—	—	-1.94%
RVMD	Revolution Medicines, Inc.	$45.2B	-25.55	—	—	+0.76%
BIIB	Biogen	$33.1B	24.16	3.34	13.8%	+0.78%
NBIX	Neurocrine Biosciences Inc	$16.1B	22.81	4.77	20.9%	+0.33%
EXEL	Exelixis, Inc.	$14.7B	17.03	6.02	35.3%	+1.00%
HALO	Halozyme Therapeutics, Inc.	$12.6B	30.39	7.55	24.9%	+1.01%
TECH	Bio-Techne	$11.4B	62.48	9.35	15.0%	+0.21%
KRYS	Krystal Biotech, Inc.	$11.0B	45.52	24.95	54.8%	+0.58%
APGE	Apogee Therapeutics, Inc.	$10.2B	-34.57	—	—	+0.04%
KYMR	Kymera Therapeutics, Inc.	$9.7B	-32.51	—	—	-1.24%
RGEN	Repligen Corp	$9.6B	230.53	12.20	5.3%	-1.87%
PCVX	Vaxcyte, Inc.	$9.1B	-8.56	—	—	-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.